Antibacterial activity of a human monoclonal antibody to haemophilus influenzae type B capsular polysaccharide.
Human splenic lymphocytes were fused with a new mutant human myeloma cell line (HFB-1) to produce hybridomas that secrete human monoclonal antibodies. A cloned hybridoma line was selected that secretes IgG antibodies reactive with Haemophilus influenzae type b polyribosylribitolphosphate (PRP) capsular polysaccharide. This human monoclonal antibody was active in an in-vitro neutrophil-mediated bactericidal assay, and provided significant protection in an animal model of H. influenzae type b disease. Human monoclonal antibody to H. influenzae type b may have prophylactic value in man, particularly in infants who do not produce protective antibody after active immunisation with PRP.
D000911:Antibodies, Monoclonal / Q000276:immunology*; D000918:Antibody Specificity; D001428:Bacterial Vaccines / Q000627:therapeutic use; D002675:Child, Preschool; D006192:Haemophilus Infections / Q000517:prevention & control; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D006825:Hybridomas / Q000378:metabolism; D007074:Immunoglobulin G / Q000096:biosynthesis; D007223:Infant; D010428:Pentosephosphates / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology*
D000911:Antibodies, Monoclonal; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D010428:Pentosephosphates; D011135:Polysaccharides, Bacterial; C003191:polyribose phosphate